NEW YORK–(BUSINESS WIRE)–Viramal, (“the Company”), an emerging specialty pharmaceutical company
developing therapeutics that improve the quality of women’s health,
today announced that the Company’s CEO, Oliver Bates, will present at
the 2016 BIO International Convention in San Francisco. The presentation
will take place on Tuesday, June 7, 2016 at 3:15 p.m. Pacific Time in
the West Presentation Theater 4 at the Moscone Center in San Francisco,
California. Mr. Bates will be joined by Viramal’s Chairman, William
Mr. Bates will outline Viramal’s robust women’s health clinical
development pipeline and strategy to produce a step change in existing
female healthcare products, as well as develop innovative products that
target unmet therapeutic areas, by leveraging novel platform delivery
technologies that offer greater safety and efficacy. Elegant™ Vaginal
Moisturizer (for the treatment of vaginal atrophy) and other products
from the Elegant Vaginal platform (both OTC and prescription), plus
Viramal’s only men’s health product, TestoCream (transdermal delivery in
an elegant cream base without alcohol), are available for out-licensing.
The Company’s platform delivery technologies are also available for
out-licensing for applications beyond women’s health. The presentation
will be available in the News
section of the Company’s website, www.viramal.com.
To schedule a meeting with Viramal’s management team at the conference,
use the BIO
One-on-One Partnering™ system for registered participants or contact
Katja Buhrer in the Investor Relations department at firstname.lastname@example.org.
Viramal will be taking meetings June 6-9.
Viramal is an emerging specialty pharmaceutical company focused on the
development of therapeutics that improve the quality of women’s health.
The Company’s well-recognized management team has pioneered
market-leading products in fertility and female sexual health, having
successfully developed, licensed and sold Crinone®, Replens® and
RepHresh®. Viramal produces a step change in these existing products, as
well as develops innovative products that target unmet therapeutic
areas, by leveraging novel platform delivery technologies that offer
greater safety, efficacy and patient acceptability with far fewer side
effects. The Company’s robust women’s health clinical development
pipeline includes treatments for fertility, menopausal hormone therapy,
contraception and sexual health. In addition, Viramal’s only male
product, TestoCream (transdermal delivery of testosterone), has shown
81% success in a partially completed Phase III study. Please visit www.viramal.com
for more information.
BIO is the world’s largest trade association representing biotechnology
companies, academic institutions, state biotechnology centers and
related organizations across the United States and in more than 30 other
nations. BIO produces the BIO International Convention, the world’s
largest gathering of the biotechnology industry, along with
industry-leading investor and partnering meetings held around the world.
MBS Value Partners